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Abstract
Background: Invasion is a hallmark of a malignant tumor, such as a glioma, and the progression is
followed by the interaction of tumor cells with an extracellular matrix (ECM). This study examined
the role of type I collagen in the invasion of the malignant human glioma cell line T98G by the
introduction of the human collagen type I α1 (HCOL1A1) gene.
Results: The cells overexpressing HCOL1A1 were in a cluster, whereas the control cells were
scattered. Overexpression of HCOL1A1 significantly suppressed the motility and invasion of the
tumor cells. The glioma cell growth was markedly inhibited in vitro and in vivo by the overexpression
of HCOL1A1; in particular, tumorigenicity completely regressed in nude mice. Furthermore, the
HCOL1A1 gene induced apoptosis in glioma cells.
Conclusion: These results indicate that HCOL1A1 have a suppressive biological function in glioma
progression and that the introduction of HCOL1A1 provides the basis of a novel therapeutic
approach for the treatment of malignant human glioma.
Background
The processes of tumor cell invasion into the stromal tis-
sue are closely related to the interactions between tumor
cells and extracellular matrix (ECM). Furthermore, the
alteration of the expression and modification of ECM pro-
teins in tumor cells is relevant to their invasiveness into
surrounding normal tissue. For example, loss of fibronec-
tin, which is an ECM glycoprotein from the cell surface,
has been indicated to be closely associated with malignant
transformation of cells [1]. It was then shown that the
overexpression of fibronectin in human fibrosarcoma
cells was able to suppress the motility and growth poten-
tial of tumor cells [1]. Collagens are the most important
components of ECM and play an important role in cell
adhesion, movement, differentiation, proliferation, and
metastasis of tumor cells. Recently, fragments of type IV,
type XV, and type XVIII collagen, which are components
of various basement membranes, have been extensively
studied for their potential in the reduction of angiogenesis
and tumorigenesis [2,3]. Endostatin, a non-collagenous
C-terminal domain (NC1) fragment of type XVIII colla-
gen, was the first endogenous fragment characterized with
anti-angiogenic properties [4]. The NC1 fragments of type
XV collagen and type IV collagen were also identified as an
endogenous angiogenesis inhibitor [5-11].
Type I collagen is a fibrillar collagen that consists of two
polypeptide chains, the α1(I) chain and the α2(I) chain.
Published: 20 June 2007
Cancer Cell International 2007, 7:12 doi:10.1186/1475-2867-7-12
Received: 27 April 2007
Accepted: 20 June 2007
This article is available from: http://www.cancerci.com/content/7/1/12
© 2007 Honma et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Cancer Cell International 2007, 7:12 http://www.cancerci.com/content/7/1/12
Page 2 of 9
(page number not for citation purposes)
Most of type I collagen molecules are distributed as heter-
otrimers [α1(I)]2α2(I), and a small number of molecules
exist as homotrimers [α1(I)]3. Although type I collagen is
the most abundant collagen in skin, bone, and other tis-
sues and organs, no type I collagen molecule and/or frag-
ments have been demonstrated to have suppressive
efficacy on malignant phenotypes of a tumor. However,
variations in the production of type I collagen by tumors
have been reported in the relationship with tumor pro-
gression, and transformed cells generally synthesize less
collagen than their counterparts [12-15]. The differential
expression between hepatocellular carcinomas and nor-
mal liver was revealed, and type I collagen was down-reg-
ulated in hepatocellular carcinomas [15]. In a
neuroblastoma, type I collagen biosynthesis is a helpful
marker for studying specific patterns of transdifferentia-
tion associated with the loss of malignant potential [16].
In addition, type I collagen was able to inhibit growth and
malignant transformation in human glioma cells [17,18].
In the present study, a type I collagen gene was introduced
to glioma, which is characterized by marked tumor cell
proliferation and extensive local invasion, in order to
examine the inhibitory effects of the overexpressed
HCOL1A1 on invasion and tumorigenesis. The results
showed that overexpression of HCOL1A1 in malignant
glioma cells suppressed cell proliferation, inhibited cell
motility and invasiveness, and arrested tumor formation
in vivo.
Results
Overexpression of HCOL1A1 in T98G cells
Human type I collagen cDNA (HCOL1A1) was transfected
into the human malignant glioma cell line T98G. Twenty-
nine colonies of G418-resistant cells were cloned, and
G418-resistant clones were screened for expression of
HCOL1A1 by immuno-detection with a polyclonal anti-
α1(I) collagen antibody. Two independent clones stably
over-expressing HCOL1A1, designated HOCL1A1-I and
HCOL1A1-II, were isolated. By immunocytochemical
staining HCOL1A1-I and HCOL1A1-II cells showed
strong immunoreactivity, while HCOL1A1 peptides were
not detectable in wild cells and Mock cells (Fig. 1a).
Expression of HCOL1A1 peptides were also confirmed in
the whole cell lysates and the conditioned medium from
HCOL1A1-transfected cells by immunoblot analysis.
Although immunoreactive protein bands, which are
absent in parental wild cells and Mock-transfected cells,
were clearly identified, HCOL1A1 peptides were digested
into fragments and did not fold into triple helices charac-
teristic of type I collagen (data not shown).
The cell densities of the HCOL1A1-transfected cells (4
days) were significantly different from that of wild cells
and Mock cells (Fig. 1b): this was clearly shown that the
growth inhibition of HCOL1A1-transfected cells, as well
as they were tightly cell-cell contacted in clusters, while
control cells were dispersed and spindle-shaped in scatter-
Morphological changes of the HCOL1A1-overexpressing T98G cells Figure 1
Morphological changes of the HCOL1A1-overexpressing T98G cells. Wild cells (Wild), control transfected cells (Mock), and 
HCOL1A1-transfected cells (HCOL1A1-I and HCOL1-II) were seeded at 1 × 105 cells on 6-cm culture dishes and grown for 2 
to 4 days. (a) Immunocytochemical staining of T98G cells (day 2). HCOL1A1 peptides were immunostained with polyclonal 
anti-α1(I) collagen antibody. Scale bar: 100 μm. (b) Phase-contrast photomicrographs of T98G cells (day 4). Scale bar: 200 μm.
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ing as usual (Fig. 1a). These results suggest that forced
expression of HCOL1A1 resulted in apparent cell density
changes in T98G cells.
Inhibition of cell growth by HCOL1A1
The effect of HCOL1A1 expression on the growth of T98G
cells was further evaluated kinetically (Fig. 2). Cell growth
was significantly suppressed in HCOL1A1-I and
HCOL1A1-II cells, P < 0.001 and P < 0.0001 versus Mock
cells, respectively. These results showed that overexpres-
sion of HCOL1A1 was able to inhibit the growth of T98G
cells in vitro.
Suppression of tumor cell motility and invasion by 
HCOL1A1
Whether the HCOL1A1 peptide inhibits tumor cell motil-
ity was examined. (Fig. 3a, 3b). The motility of
HCOL1A1-transfected cells was dramatically lower than
that of Mock cells. The migration of HCOL1A1-I and
HCOL1A1-II cells was inhibited more than 80% as com-
pared to Mock cells.
Furthermore, the effect of HCOL1A1 overexpression on
the invasiveness of T98G cells was assessed. Figure 3c and
3d shows the ability of these cells to invade through the
reconstituted Matrigel ECM. HCOL1A1-transfected cells
displayed a significant reduction in invasion of more than
55%.
In the in vitro invasion model using reconstituted base-
ment membrane wafers, HCOL1A1-I cells hardly invaded
the Matrigel wafer on day 7 (Fig. 3e). In contrast, a
number of Mock cells invaded the Matrigel wafer. Thus, it
was clearly demonstrated that the HCOL1A1 peptide sup-
pressed the cell motility and invasion of T98G cells.
Inhibition of tumor formation in vivo by HCOL1A1
To assess the effects of forced HCOL1A1 expression on
T98G glioma cell growth in vivo, HCOL1A1-I cells and
Mock cells were injected into nude mice s.c., and the
tumor volumes were determined 87 days later (Fig. 4).
Figure 4b shows that HCOL1A1-I cells had grown more
poorly and formed smaller nodules than the Mock cells.
At 87 days, the animals were sacrificed, and complete
tumor regression was observed in the mice transplanted
with HCOL1A1-I cells. In contrast, the control cell-trans-
planted animals had developed large tumors of around
1,000 mm3. These results suggest that the introduction of
HCOL1A1 was able to function as a growth suppressor in
human glioma cells in vivo.
Induction of apoptotic cells in vitro by HCOL1A1
The effect of overexpressed HCOL1A1 on the apoptosis of
glioma was studied by the TUNEL assay (Fig. 5). Figure 5a
shows that numerous apoptotic cells were detected in
HCOL1A1-transfected cells, whereas apoptotic cells were
scarcely seen in the Mock cells. The number of apoptotic
cells was counted in the microscopic fields, and the per-
centage of apoptotic cells is revealed in Figure 5b. The
apoptosis rates of HCOL1A1-I and HCOL1A1-II were
17% and 29%, respectively. In contrast, Mock cells
showed less than 1% of apoptotic cells. Therefore, the
over-expression of HCOL1A1 induced the apoptosis of
T98G glioma cells and this may partially contribute to the
growth suppression of HCOL1A1 tumors in mice.
Discussion
The present study shows that the overexpression of
HCOL1A1 in T98G malignant glioma cells markedly
changed the cell morphology and significantly suppressed
the motility and invasion of cells. In addition, the inhibi-
tion of glioma cell growth was indicated in vitro and in
vivo; in particular, tumorigenicity had regressed com-
pletely in nude mice. Moreover, HCOL1A1 induced the
apoptosis of glioma cells, and this finding suggested that
apoptosis participates in a mechanism for the suppression
of malignancy of T98G glioma cells by forced expression
of HCOL1A1. Interestingly, overexpression of HCOL1A1
in 293 cells, which are transformed human embryo kid-
ney cell line and do not express HCOL1A1, showed no
influence on the cell morphology, growth and apoptosis
induction (data not shown). This finding suggests that
ectopic forced expression of HCOL1A1 protein in cells
dose not cause of unfolded protein response which
induces apoptosis, however, the effects of accumulation
of unfolded HCOL1A1 protein on various cell types
should be further considered.
Inhibition of T98G cell growth in vitro by HCOL1A1 expres- sion Figure 2
Inhibition of T98G cell growth in vitro by HCOL1A1 expres-
sion. The graph shows the growth curves of Mock cells 
(Mock, ❍) and HCOL1A1-transfected cells (HCOL1A1-I, ● ; 
HCOL1A1-II, ■). The same number of cells were seeded and 
cultured for 5 days. At each time point, the cells were 
assayed for proliferation. Each value represents mean ± SD 
(n = 8).
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It has been pointed out that loss of ECM control is a char-
acteristic feature in malignant tumor progression toward
invasion [19]. In glioma cells, the expression of ECM com-
ponents, such as decorin, tenascin, vitronectin, laminin,
fibronectin, type I collagen, type IV collagen, neuronal cell
adhesion molecule (NCAM), N-cadherin, and beta-cat-
enin, dramatically changes during tumor progression, and
these ECM proteins have been reported to play a signifi-
cant role in the migration and invasion of gliomas [18,20-
29]. As an example of glioma therapy using ECM protein,
decorin, which is poorly expressed by glioma cell lines,
was ectopically expressed in glioma cells and successfully
used to abrogate the growth of experimental gliomas
[20,30,31]. Similarly, the overexpression of type I colla-
gen should be useful for suppression of glioma progress.
It has become clear that ECM proteins have unknown
physiological cell functions. Recently, the biological func-
tions of various collagen fragments have been described;
fragments of type IV, type XV, and type XVIII collagen
have been noted for their potential [2,3]. Type IV, type XV,
and type XVIII collagen are major components of various
basement membranes. Although their functional role in
basement membrane architecture is well known, the NC1
fragments of these collagens are involved in the regulatory
functions of various cellular events, such as angiogenesis,
Suppression of T98G cell motility and invasion by overexpression of HCOL1A1 Figure 3
Suppression of T98G cell motility and invasion by overexpression of HCOL1A1. Mock cells (Mock) and HCOL1A1-transfected 
cells (HCOL1A1-I and HCOL1A1-II) were added to a transwell chamber and the cell motility was evaluated. (a) The migrated 
cells were stained and photographed under the microscope at × 100 magnification. (b) The number of migrated cells was 
counted, and the results represent a percentage of Mock cells. Each value is a mean ± SD (n = 4). *, P < 0.001, when tested 
against the Mock. Mock cells (Mock) and HCOL1A1-transfected cells (HCOL1A1-I and HCOL1A1-II) were added to a tran-
swell chamber coated with Matrigel and the cell invasion was evaluated. (c) The invaded cells were stained and photographed 
under a microscope at × 100 magnification. (d) The number of invaded cells was counted, and the results are expressed as a 
percentage of Mock cells. Each value is a mean ± SD (n = 4). *, P < 0.001, **, P < 0.01 when tested against the Mock. The cell 
invasion into an in vitro invasion model was evaluated using reconstituted basement membrane wafers. (e) Mock cells (Mock) 
and HCOL1A1-transfected cells (HCOL1A1-I) were plated onto Matrigel wafers. On days 3 and 7 after plating, Matrigel wafers 
and adherent cells were fixed, and sections were stained with hematoxylin and eosin. Magnification, × 200.
b
dCancer Cell International 2007, 7:12 http://www.cancerci.com/content/7/1/12
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Inhibition of tumor formation of T98G cells in vivo by introduction of the HCOL1A1 gene Figure 4
Inhibition of tumor formation of T98G cells in vivo by introduction of the HCOL1A1 gene. T98G cells were implanted s.c in the 
forelegs of nude mice, and the tumor volume was measured at each time point. (a) Tumor formation in nude mice at 87 days 
after inoculation with Mock cells (Mock) or HCOL1A1-transfected cells (HCOL1A1-I). Scale bar, 1 cm. (b) The in vivo tumor 
growth of HCOL1A1-transfected cells (HCOL1A1-I, n = 4) was compared with that of Mock cells (Mock, n = 2).
a
bCancer Cell International 2007, 7:12 http://www.cancerci.com/content/7/1/12
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tumorigenesis, migration, proliferation, apoptosis, and
morphogenesis, which are distinct from those of original
intact molecules [2-11,32-36]. Endostatin, which is an
NC1 fragment of type XVIII collagen, has been extensively
studied in the angiogenesis field [4,37,38]. It has been
reported that endostatin inhibits tumor cell invasion, as
well as HCOL1A1 peptides, which were presented here.
Endostatin inhibits tumor cell invasion by blocking the
activation of latent matrix metalloprotease-2, -9, and -13
[39-41]. However, in this study, there was no difference in
the level of activated MMP-2 and MMP-9 between
HCOL1A1-transfected cells and Mock cells by gelatin
zymography analysis (data not shown). This finding sug-
gests that the HCOL1A1 peptide may have a unique func-
tion as a suppressor of tumor cell invasion that is distinct
from that of NC1 fragments of basement membrane col-
lagens. It was demonstrated that endostatin suppresses
cell proliferation in vitro and inhibits the growth of pri-
mary tumors and metastases by induction of apoptosis
[42-44]. Similarly, the expression of HCOL1A1 peptides
caused inhibition of tumor cell growth in vitro and com-
plete regression of tumors in nude mice. Moreover,
HCOL1A1 peptides induced apoptosis in glioma cells.
Thus, HCOL1A1 peptides, as well as endostatin and other
NC1 fragments of collagens, should also have a potential
for anti-tumorigenesis. Interestingly, type I collagen is a
fibrillar collagen, whereas fragments of collagens, which
have so far been reported to inhibit tumor progression,
are derived from basement membrane collagens. The
HCOL1A1 peptides, which are derived from fibrillar col-
lagen, may be novel inhibitors of tumor growth and inva-
sion. In this report, the mechanism for the suppression of
malignancy of T98G glioma is not evident, but it should
become clear with further study.
Induction of apoptotic T98G cells in vitro by overexpression of HCOL1A1 Figure 5
Induction of apoptotic T98G cells in vitro by overexpression of HCOL1A1. Mock cells (Mock) and HCOL1A1-transfected cells 
(HCOL1A1-I and HCOL1A1-II) were assayed for apoptosis using the in situ TUNEL method. (a) The photomicrographs of 
Apoptotic cells. Magnification, × 200. (b) The percentage of apoptotic cells represents the mean ± SD (n = 5, duplicate experi-
ment). *, P < 0.001, when tested against the Mock.
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Recently, significant technical advances in the treatment
of gliomas have emerged, and gene therapy, in particular,
is noted as a potent therapeutic strategy. The major
approaches of gene therapy to glioma are based on apop-
tosis-related gene therapy [45], antiangiogenesis therapy
[46,47], and immunotherapy [48,49]. Several ECM com-
ponents and their fragments, such as decorin [20,30,31]
and endostatin [46,50-54] are being tried as potential tar-
gets for glioma gene therapy. The HCOL1A1 gene may
also be a good candidate as gene medicine for a novel
therapy against glioma.
Conclusion
In summary, the tumor growth and invasion of malignant
human gliomas were markedly suppressed by the intro-
duction of HCOL1A1. The suppression of a malignant
phenotype of glioma cells by HCOL1A1 provides the
basis of a novel therapeutic approach.
Materials and methods
Cell culture
The human glioma T98G cells were derived from glioblas-
toma and obtained from the American Type Culture Col-
lection. Cells were maintained and passaged in a
minimum essential medium (MEM) supplemented with
10% fetal bovine serum (FBS), 1% nonessential amino
acids, and 1 mM sodium pyruvate at 37°C.
HCOL1A1 expression plasmid
An α1 chain of the human type I procollagen expression
vector, pCXN2/HCOL1A1, was constructed as follows.
The cDNA of HCOL1A1 was cloned from a human heart
cDNA library, and a partial cDNA fragment was synthe-
sized by RT-PCR using mRNA of a normal human skin
fibroblast. cDNA encoding the full-length HCOL1A1 gene
was assembled from these fragments. The full-length
HOCL1A1 cDNA was cloned into the downstream of the
CAG promoter of a pCXN2 expression vector containing
the neomycin resistance gene.
Cell transfection
Cells were transfected with pCXN2/HCOL1A1 or pCXN2
without an insert, as a Mock, by using LipofectAMINE
2000 (Invitrogen Corporation, CA) according to the man-
ufacturer's protocol. Cells were selected in a medium con-
taining 0.8 mg/ml of G418. G418-resistant colonies were
cloned and expanded.
Immunocytochemical staining
T98G cells (1 × 105) were grown for 2 to 4 days on 6-cm
culture dishes and fixed with cold methanol at -20°C for
5 min. The cells were permeated with 0.02% Triton X-100
in PBS for 15 min and pretreated with 3% H2O2 in meth-
anol for 15 min to quench endogenous peroxidase activ-
ity. The cells were blocked with Block Ace (Dainippon
Pharmaceutical Co., Ltd., Osaka, Japan) overnight at 4°C
and incubated with polyclonal anti-α1(I) collagen anti-
body (L-19) (1:60) (Santa Cruz Biotechnology, Inc., CA)
at 37°C for 1 h. Bound primary antibodies were labeled
with biotinylated IgG antibodies (1:500) (Santa Cruz Bio-
technology, Inc., CA) at 37°C for 15 min and incubated
with streptavidin-peroxidase at 37°C for 20 min.
HCOL1A1 peptides were visualized with diaminobenzi-
dine, and nuclei were counterstained with hematoxylin.
In vitro growth assay
Individual clones were seeded in 96-well plates at a den-
sity of 5 × 102 cells per well in 100 μl of a culture medium.
At each time point, the cells were assayed for proliferation
with TetraColor One, a cell-proliferation assay reagent
(Seikagaku Co., Tokyo, Japan), according to the recom-
mended method; they were then measured for absorb-
ency at the well at 450 nm with a reference wavelength at
650 nm.
In vitro invasion and motility assay
In vitro invasion assays were performed using a Matrigel
invasion chamber (8-μm pore size, Becton Dickinson,
Bedford, MA). A suspension of 2.5 × 104 cells in 0.5 ml of
a serum free medium, Cosmedium 001, was added to the
Matrigel chamber. The chambers were incubated at 37°C
for 24 h in a 95% air/5% CO2 incubator. The cells on the
lower surface of the membrane were stained with Diff-
Quik stain (Kokusaisiyaku, Kobe, Japan). The invadin
cells were photographed under a microscope at × 100
magnification and counted in five fields of four mem-
branes.
A cell motility assay was performed in a similar manner
except that the 8-μm pore size PET membrane was not
coated with Matrigel.
Tumor invasion into a matrigel wafer
The reconstituted basement membrane wafers were made
by adding 1 ml of Growth Factor Reduced Matrigel (Bec-
ton Dickinson, MA) to a well of a 24-well plate and gelled
at 37°C for 30 min. 1 × 105 cells were plated onto the sur-
face of each wafer. On days 3 and 7 after plating, Matrigel
wafers and adherent cells were fixed with 4% paraformal-
dehyde in PBS for 1 h. The wafers were then dehydrated
through a graded ethanol series and embedded in paraf-
fin. Sections were cut and stained with hematoxylin and
eosin.
In vivo tumor formation
T98G cells (4.3 × 106) were implanted subcutaneously in
100 μl of a 1:1 mixture of a culture medium and Growth
Factor Reduced Matrigel in the forelegs of the nude mice
according to the method described by Rubenstein et al.
[55] and Teicher et al. [56]. The tumor volume was meas-Cancer Cell International 2007, 7:12 http://www.cancerci.com/content/7/1/12
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ured with a caliper and calculated using the formula
width2 × length × 0.5. Animal experiments in the present
study were performed in compliance with the guidelines
of the Institute for Laboratory Animal Research, National
Cancer Center Research Institute.
Apoptosis assay
In the normal growth medium, 1.8 × 105 cells were seeded
onto 6-cm culture dishes. After 24 h, the cells were rinsed
and cultured in a serum-free medium, Cosmedium 001,
which contained no protein except insulin and transferrin
and was supplemented with sodium ascorbate (50 μg/ml)
to avoid the effects of several ECM proteins carried by the
serum. Five days later, the cells were assayed for apoptosis
by the TUNEL method with the In Situ Cell Death Detec-
tion Kit, POD (Roche, Switzerland) according to the man-
ufacturer's instructions. Apoptotic cells were identified by
diaminobenzidine staining, and nuclei were counter-
stained with hematoxylin. The number of apoptotic cells
was counted in five microscopic fields.
Statistical analysis
The results are given as means ± SD. Student's t-test was
performed for statistical evaluation, with P < 0.05 consid-
ered significant.
Abbreviations
ECM, extracellular matrix; HCOL1A1, human collagen
type I α1.
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